News

Athira Pharma’s fosgonimeton (ATH-1017) shows promise as a therapy for neurodegenerative conditions including Parkinson’s disease, according to data presented at the recent International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2024), in Portugal. The investigational small molecule demonstrated “encouraging pro-cognitive effects” in the exploratory…

An antibody that targets a naturally occurring modified form of alpha-synuclein, a protein that forms into toxic clumps in the brain of people with Parkinson’s, delays its buildup and spread in vivo in a mouse model of the disease. This modified form of nitrated alpha-synuclein is being explored by…

An experimental therapy called ASHA-091, which was seen to restore normal mitochondria function and possibly be disease modifying in a mouse model of Parkinson’s disease, may soon be moving into clinical trials, its developer, Asha Therapeutics, reports. Problems with the workings of mitochondria, a cell’s…

NodThera’s potential oral therapy for Parkinson’s disease, NT-0796, continues to show promise in countering damaging inflammation in treated patients, according to new findings from a Phase 1b/2a clinical trial. Treatment with NT-0796 for 28 days safely reduced pro-inflammatory markers in the patients’ cerebrospinal fluid (CSF, the liquid surrounding…

Risvodetinib, an oral therapy being developed by Inhibikase Therapeutics for Parkinson’s disease, appears to stabilize disease status and severity, according to data covering 25 patients who finished 12 weeks of dosing in an ongoing Phase 2 clinical trial. Over those trial weeks, clinician and patient impressions of disease…

Treatment with UB-312, a vaccine designed to trigger an immune response against toxic clumps of the alpha-synuclein protein, reduced these damaging aggregations in people with Parkinson’s disease in a Phase 1 trial. The findings, announced by UB-312’s developer Vaxxinity and presented at the at the AD/PD 2024…

Use of bemdaneprocel (BRT-DA01), BlueRock Therapeutics’ investigational cell-based therapy, was found to be safe and well tolerated among people with Parkinson’s disease 1.5 years after treatment in a Phase 1 clinical trial. Moreover, the data also showed both that cells survived in the brain even after patients stopped…

bit.bio and The Michael J. Fox Foundation (MJFF) are teaming up in a multiyear effort to develop a range of human cell products for research and drug discovery in Parkinson’s disease. Under the new collaboration agreement, the MJFF will fund specific research on a project-by-project basis, with bit.bio…

Allyx Therapeutics said it will begin a clinical trial by the end of the month to test its lead candidate ALX-001, a disease-modifying therapy for neurodegenerative conditions, in people with Parkinson’s disease. The trial will test the treatment’s safety when administered for 28 days. The U.S. Food and…

By activating an enzyme known as beta-glucocerebrosidase, or GCase, the experimental therapy GT-02287 is able to improve nerve survival and reduce the dysfunction of lysosomes — structures that work like cellular garbage disposal systems and clear away molecular debris — in cell models of Parkinson’s disease. The Gain…